September 2024 – Kimera Biotecnology was the only startup from Ribeirão Preto to have its patent approved in the call for proposals, aimed at supporting innovations crucial to the Brazilian economy.
Kimera Biotechnology, a startup incubated at SUPERA Innovation and Technology Park in Ribeirão Preto, has been approved in the Intellectual Property Call for Proposals by the Brazilian Funding Agency for Studies and Projects (FINEP). The company received R$ 5 million to develop a new technology focused on animal health in collaboration with the University of São Paulo (USP). The project, which aims to create an innovative hormone for animal reproduction, was the only patent from USP in Ribeirão Preto to be approved.
The FINEP Intellectual Property Call for Proposals primarily aims to foster research and innovations that can have significant impacts on the Brazilian economy, assisting in the transition of discoveries from academia to the marketplace. In a highly competitive environment, Kimera’s approval represents a validation of the project’s potential, highlighting SUPERA Park’s role as a catalyst for technological innovations in Brazil.
Kimera Biotechnologies’ co-founders, Camillo Andrade and Mayb Fiats Andrade, commented on the significance of the achievement: “The importance of this achievement for Kimera is immense, as it was an extremely competitive call – and being approved confirms that we are on the right path, that we must not give up and need to keep moving forward. Developing medications in the field of animal health is neither quick nor easy, as there are many challenges, and we’ve faced many of them over Kimera’s 10 years of existence. We are extremely pleased with this achievement.”
Kimera Biotechnology is a pioneer in the development and patenting of Recombinant Equine Chorionic Gonadotropin (r-eCG), a hormone used to optimize reproductive processes in animals. This product, fully developed in the laboratory, represents an unprecedented innovation in the livestock sector, offering an effective solution to improve animal reproduction.
With the funding obtained through FINEP, Kimera Biotechnology plans to invest in additional testing to further refine the technology and hire new professionals who can contribute to advancing the project. The company hopes that this development will boost the animal health sector, providing new tools for rural producers and contributing to improved productivity in the field.
A fertile environment for innovation
SUPERA Park, where Kimera Biotechnology is incubated, has established itself as one of Brazil’s leading innovation hubs, offering a robust infrastructure and an ecosystem conducive to the growth of startups and technology-based companies. Kimera’s approval in the FINEP call reinforces the park’s excellence in fostering the development of high-impact innovations.
For SUPERA Park, Kimera’s achievement is a clear example of the success that can be achieved when the right support and infrastructure are provided for technological development. SUPERA Park’s Technical Director, Prof. Lauro Wichert, commented on the relevance of this approval: “Seeing a startup like Kimera reach this level of recognition is a great satisfaction for us at SUPERA Park. It is proof that we are on the right track by providing the conditions for tech companies to develop and bring innovations that benefit society.”
Strategic partnership with USP
The collaboration between Kimera Biotechnology and USP Ribeirão Preto was essential for the project’s approval in the FINEP call. Partnering with one of the country’s most renowned academic institutions not only ensured the technical quality of the project but also strengthened the company’s innovation capacity. USP and Kimera hold the only patent from Ribeirão Preto approved in the call, and this over 10-year partnership was key to the scientific validation of the r-eCG hormone.
On September 26, Kimera will participate in an event organized by the Federation of Industries of the State of São Paulo (FIESP), where the partnership between USP and FINEP will be one of the main topics. During the event, Kimera will present its project, highlighting the importance of collaboration between academia and the private sector in developing new technologies that can positively impact the market.
With the support of FINEP and the partnership with USP, Kimera is positioned to expand its operations and bring its innovation to market. The company, already a pioneer in the production of recombinant molecules for animal health, now has the potential to become a reference in the sector, not only in Brazil but also in international markets.
SUPERA Park, in turn, continues to strengthen its position as a center of excellence in innovation, attracting more companies seeking an environment conducive to the development of advanced technologies. Kimera Biotechnologies’ approval in the FINEP call is a testament to the park’s success in promoting innovation and collaboration between academia and industry, creating a virtuous cycle of technological development that benefits society as a whole.
ABOUT SUPERA Park
SUPERA Park is managed by FIPASE and hosts 78 companies in total, with 49 in the SUPERA Technology-based Business Incubator and 29 enterprises in the Innovation Condominium. The Technology Park is expanding with the urbanization of lots for company installations, seven of which are already in the process of being occupied, along with the newly inaugurated Container Park, a new business complex featuring business modules, a cafeteria, a training room, and the UP-Lab SENAI unit. More information about the Park is available at http://superaparque.com.br/.
AIs. Comunicação e Estratégia
Ligia Gabrielli – (41) 98700-2363
Dimas Rodrigues – (41) 99159-4452
